Outcome of the Board Meeting held on Monday, 10 November 2025 and Submission of the Unaudited Financial Results and Limited Review Report on Financial Result for the half year ended on ....

Revenue Growth 20pctPat Growth 25pctNegative Operating CashflowResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+7.3%Reaction day

₹41.10

prior close

₹42.99

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.4%+7.7% vs market

Pharmaceuticals peers, median of 155sector-0.1%+7.4% vs sector

On the reaction day the stock moved 7.7 pts more than Nifty Microcap 250 and 7.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.2

10m

+1.2

15m

+1.2

30m

+1.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+7.3-0.4+7.7-0.1+7.4

Next day

+5.8-0.6+6.5-0.8+6.6

+2.2+0.3+1.9+0.2+2.0

+0.4+0.2+0.2-0.0+0.4

+2.3+0.1+2.2+0.2+2.1

+4.6+0.7+3.9+0.3+4.3

+0.1-0.3+0.4-0.9+1.0

15d

-1.6-2.0+0.5-1.4-0.1

-10.9-5.7-5.3-3.6-7.3

-17.9-7.8-10.1-6.2-11.7

+4.5-4.6+9.1-6.9+11.4

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 155Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Shelter Pharma's board approved standalone unaudited financial results for the half year ended 30 September 2025, along with an unmodified limited review report from Mendajiwala & Co. Revenue from operations rose to ₹3,329.29 lakhs from ₹2,405.67 lakhs in H1 FY25, a year-on-year jump of about 38%. Profit after tax climbed to ₹450.07 lakhs (vs ₹353.64 lakhs), up roughly 27% YoY, with basic EPS at ₹3.89 (vs ₹3.06). Total assets and liabilities expanded to ₹6,689.54 lakhs (vs ₹4,833.55 lakhs at March 2025), driven mainly by a sharp rise in long-term borrowings to ₹1,350.84 lakhs (from ₹93.16 lakhs). The auditor also certified that ₹930.35 lakhs raised via convertible warrants was fully used for working capital with no deviation. No investor complaints were reported during the period.

Likely market impact

Strong top-line and bottom-line growth is positive for shareholders, but the sizeable negative operating cash flow of ₹869 lakhs and a sharp jump in long-term borrowings flag working-capital strain that investors should monitor closely.